Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
95 hedge funds and large institutions have $347M invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2013 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 9 closing their positions.
1,391% more call options, than puts
Call options by funds: $11M | Put options by funds: $735K
322% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 9
192% more capital invested
Capital invested by funds: $119M → $347M (+$228M)
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
42% more funds holding
Funds holding: 67 → 95 (+28)
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$25M |
| 2 |
BC
Broadfin Capital
New York
|
+$12.8M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
+$4.69M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.77M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$3.01M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
101
Virtu KCG Holdings
New York
| – | -$74K | -21,947 | Closed |
|
102
JP Morgan Chase
New York
| – | -$64K | -19,025 | Closed |
|
|
TH
103
Timber Hill
Greenwich,
Connecticut
| – | -$42K | -12,667 | Closed |
|
|
SSG
104
Summit Securities Group
New York
| – | -$8K | -2,400 | Closed |
|
HZNP Hedge Fund Activity: Q4 2013 in Review
95 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q4 2013, worth a combined $347M — up 192% from $119M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new HZNP positions and 9 closed out — a net gain of 29 holders — while 32 added to existing stakes and 18 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $25M. The largest seller was Fidelity Investments, cutting an estimated $12M.
- 95 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q4 2013, up from 67 in Q3 2013.
- Funds reported $347M of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q4 2013, up 192% quarter-over-quarter.
- 38 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q4 2013 and 9 closed out, a net change of +29 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q4 2013 was Deerfield Management, an estimated $25M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q4 2013 was Fidelity Investments, an estimated $12M sold.
Based on aggregated 13F filings for Q4 2013.